Russian Scientists to Develop World's First Drug Targeting the 'Aging Gene'
Researchers from the Institute of Biology of Aging plan to create a gene therapy drug that blocks the RAGE gene, whose activation triggers cellular aging processes, potentially extending youthfulness significantly.
From the 'Aging Gene' to a Longevity Pill: Russian Scientists' Ambitious Project to Block RAGE
Introduction
In April 2026, at a national conference in Saransk, Deputy Minister of Science and Higher Education of the Russian Federation Denis Sekirinsky made a statement that immediately grabbed global headlines: Russia is embarking on the creation of the "world's first gene therapy drug" to block the so-called "aging gene" — the RAGE receptor. The project is being implemented by the Institute of Biology of Aging and Medicine as part of the national project "New Health Preservation Technologies," with a budget exceeding 2 trillion rubles.
The development promises not merely to extend life but to influence its fundamental mechanisms by blocking a biochemical process that, according to scientists, triggers cellular aging. But does this bold claim signal a real breakthrough? To answer this question, one must understand what the mysterious RAGE receptor actually is and how ready the scientific community is to create such a medicine.
Event Details and Timeline
The official announcement took place on April 23, 2026. Speaking at a conference aligned with the "For Healthy Longevity Medicine" movement, Denis Sekirinsky announced the creation of two gene therapy drugs. The first targets the therapy of sarcopenia (age-related loss of muscle mass), and the second, the main one, aims to block the RAGE gene.
The principle is simple in description but complex in execution: the RAGE gene encodes a receptor of the same name on the surface of cells. When activated, this receptor triggers a cascade of inflammatory reactions and oxidative stress, bringing the cell closer to death and contributing to the overall aging of the organism. Scientists propose to "switch off" this mechanism by blocking the receptor to prolong the cell's "youthfulness."
Clear government-imposed deadlines have been set. Deputy Prime Minister Tatiana Golikova previously designated a time window for the start of drug production — 2028–2030. This indicates the project is not in the theoretical research stage but in an active development phase with a concrete implementation plan.
Impact and Significance
If the stated concept is successfully realized, the effect could be tectonic.
For the World and Science: Creating a RAGE antagonist would be the first case where a drug deliberately "switches off" one of the fundamental mechanisms of aging. Currently, there are more than five companies worldwide developing RAGE inhibitors, but most (for example, the US-based vTv Therapeutics with its drug azeliragon) are in Phase II clinical trials and aim to treat specific diseases — Alzheimer's disease, diabetic nephropathy, or glioblastoma. The Russian project is more ambitious: the goal is to affect aging itself as a general biological process.
For the Industry: Scientific literature clearly links the accumulation of ligands (AGEs, S100A8/A9) to RAGE activation, while an increased level of the soluble form of the receptor (sRAGE) is, conversely, associated with longevity. One study showed that healthy long-lived individuals have higher levels of protective sRAGE compared to average elderly people. Russian scientists are essentially trying to artificially create an effect that nature sometimes demonstrates on its own. Success would pave the way for a therapy that doesn't treat individual diseases but targets their root cause — age-related inflammation (inflammaging).
For Society: However, the significance of this issue lies not only in biology but also in sociology. Nina Ostanina, head of the State Duma Committee on Family Protection, commented on the development, noting that extending life is pointless if the elderly lack quality of life: "Who needs those extra years if a person has already forgotten what they are living for?" This objection reflects the main fear surrounding life extension technologies — the risk of mere survival rather than health.
Key Players' Reactions
The reaction from the international professional community has so far been restrained. On one hand, the idea of blocking RAGE is far from new and has been "in the air" for a long time (the first works on the receptor's role in aging date back to 2004). On the other hand, claims of a "world's first" drug sound bold against the backdrop of existing clinical trials of American RAGE inhibitors.
Within Russia, reactions are polarized. The authorities (represented by Deputy Prime Minister Golikova and President Putin, who launched the national project) are betting on science as a tool to solve the demographic problem. The average life expectancy for men in the RF is about 67 years, making the extension of active longevity a matter of state importance.
However, experts draw attention to the "human factor." Sources close to the Kremlin link the lobbying of the "eternal life" theme with the figure of Mikhail Kovalchuk, head of the Kurchatov Institute, who, according to rumors, "dreams of eternal life and the genome of the Russian person."
Forecast and Conclusions
Developing a RAGE blocker is a marathon, not a sprint.
Short-term forecast (next 2-3 years): We will see work with preclinical models and the refinement of gene therapy technologies. Loud statements will be accompanied by fundraising efforts and the formation of scientific consortia.
Long-term forecast (by 2030): Most likely, Russia will be able to present a functioning drug, but probably for a "therapeutic" application (for example, slowing age-related changes in severe patients or cosmonauts), rather than a mass-market "anti-aging pill" for everyone.
The main conclusion lies in a paradigm shift. Just 10 years ago, talk of blocking the "aging gene" was considered futurology or science fiction. Today, it sounds from a deputy minister's mouth like a roadmap. Russia is betting on a risky, yet potentially triumphant path — to defeat aging at the molecular level. Whether this can be accomplished faster than in the West, where the main players in the field of RAGE inhibitors are concentrated, only time and the quality of the scientific teams at the Institute of Biology of Aging will tell. But the very fact of state funding for such an ambitious task already moves the problem of aging from the category of inevitability to the category of an engineering challenge.
— Editorial Team
No comments yet.